Last checked at 5 Feb 2020 17:32
Notification and public disclosure of transactions by persons discharging
managerial responsibilities and persons closely associated with them
genedrive plc (LSE: GDR) ("genedrive" or the "Company"), the near patient molecular diagnostics company, announces that Dr Ian Gilham, Non-Executive Chairman, acquired 125,000 ordinary shares of 1.5p each ("Ordinary Shares") today at 8p per share and Tom Lindsay, Non-Executive Director, acquired 125,000 Ordinary Shares today at 8p per share.
Gino Miele, R&D Director and a PDMR, acquired 27,798 Ordinary Shares in the Company at a price of 11.56p per share yesterday and acquired 20,921 Ordinary Shares at 9.5p per share today.
Following these purchases, Dr Ian Gilham is interested in 490.674 Ordinary Shares, 1.4% of the issued share capital of the Company, Tom Lindsay is interested in 190,217 Ordinary Shares, 0.5% of the issued share capital of the Company and Gino Miele is interested in 56,719 Ordinary Shares, 0.2% of the issued share capital of the Company.
The information set out below is provided in accordance with the requirements of Article 19(3) of the EU Market Abuse Regulation No 596/2014.
1. | Details of the person discharging managerial responsibilities / person closely associated | |||||||
a. | Name | 1. Ian Gilham 2. Tom Lindsay
| ||||||
2. | Reason for the notification | |||||||
a. | Position/status | 1. Non-Executive Chairman 2. Non-Executive Director | ||||||
a. | Initial notification /Amendment | Initial notification | ||||||
3. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||||
a. | Name | genedrive plc | ||||||
b. | LEI | 213800ZYODIRZ87Y4K14 | ||||||
4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||||
a. | Description of the Financial instrument, type of instrument Identification code | Ordinary shares of 1.5 pence each
GB00B1VKB244 | ||||||
b. | Nature of the transaction | Purchase | ||||||
c. | Price(s) and volume(s) |
| ||||||
d. | Aggregated information ·; Aggregated volume ·; Price
|
N/A
| ||||||
e. | Date of the transaction | 2020-02-05 | ||||||
f. | Place of the transaction | London Stock Exchange, AIM | ||||||
1. | Details of the person discharging managerial responsibilities / person closely associated | |||||
b. | Name | Gino Miele
| ||||
2. | Reason for the notification | |||||
c. | Position/status | R&D Director | ||||
b. | Initial notification /Amendment | Initial notification | ||||
3. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
g. | Name | genedrive plc | ||||
h. | LEI | 213800ZYODIRZ87Y4K14 | ||||
4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
i. | Description of the Financial instrument, type of instrument Identification code | Ordinary shares of 1.5 pence each
GB00B1VKB244 | ||||
j. | Nature of the transaction | Purchase | ||||
k. | Price(s) and volume(s) |
| ||||
l. | Aggregated information ·; Aggregated volume ·; Price
|
N/A
| ||||
m. | Date of the transaction | 2020-02-04 | ||||
n. | Place of the transaction | London Stock Exchange, AIM | ||||
5. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
a. | Description of the Financial instrument, type of instrument Identification code | Ordinary shares of 1.5 pence each
GB00B1VKB244 | ||||
b. | Nature of the transaction | Purchase | ||||
c. | Price(s) and volume(s) |
| ||||
d. | Aggregated information ·; Aggregated volume ·; Price
|
N/A
| ||||
e. | Date of the transaction | 2020-02-05 | ||||
f. | Place of the transaction | London Stock Exchange, AIM | ||||
For further details please contact:
genedrive plc | +44 (0)161 989 0245 |
David Budd: CEO / Matthew Fowler: CFO | |
Peel Hunt LLP (Nominated Adviser and Joint Broker) | +44 (0)20 7418 8900 |
James Steel / Oliver Jackson | |
Stanford Capital Partners Limited (Joint Broker) | +44 (0)20 3815 8880 |
Patrick Claridge / John Howes | |
Walbrook PR Ltd (Media Relations & Investor Relations) | +44 (0)20 7933 8780 or genedrive@walbrookpr.com |
Paul McManus / Anna Dunphy | +44 (0)7980 541 893 / +44 (0)7876 741 001 |